Potlatch Corp (PCH) 37.47 $PCH Potlatch Corporation's

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Potlatch Corp (PCH) 37.47 $PCH

Potlatch Corporation's (PCH) CEO Mike Covey on Q1 2015 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Apr 22, 3:17PM CDT

PCH: 37.47 (-0.65)

Potlatch Corporation (Holding Company) (PCH) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Apr 22, 10:55AM CDT

PCH: 37.47 (-0.65)

Potlatch misses 1Q profit forecasts
Automated Insights - Wed Apr 22, 5:54AM CDT
SPOKANE, Wash. (AP) _ Potlatch Corp. (PCH) on Wednesday reported first-quarter net income of $5.7 million.
PCH: 37.47 (-0.65)

Potlatch misses by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 5:49AM CDT

PCH: 37.47 (-0.65)

Potlatch Corporation Reports First Quarter 2015 Results
GlobeNewswire - Wed Apr 22, 5:45AM CDT
Potlatch Corporation (Nasdaq CH) today reported net income of $5.7 million, or $0.14 per diluted share, on revenues of $134.1 million for the quarter ended March 31, 2015. Net income was $20.3 million, or $0.50 per diluted share, on revenues of $139.6 million in the first quarter of 2014.
PCH: 37.47 (-0.65)

Notable earnings before Wednesday's open
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 4:30PM CDT

DHI: 27.03 (-1.53), MKTX: 88.66 (-1.35), NLSN: 46.10 (+0.27), SEIC: 45.99 (+0.68), AZZ: 46.11 (-0.02), HBAN: 11.03 (-0.14), TDY: 109.69 (+0.48), PCH: 37.47 (-0.65), WERN: 30.29 (-1.11), NS: 65.49 (+1.78), BABY: 41.64 (+1.71), APH: 56.81 (-1.35), TEL: 70.14 (+0.13), R: 97.95 (+1.15), ANGI: 6.46 (+0.31), EVR: 50.80 (+1.28), CFG: 25.49 (+0.45), SIX: 49.97 (+1.37), EMC: 27.13 (+0.81), OC: 42.28 (-0.61), WAB: 98.61 (+2.84), BK: 42.43 (+1.39), KO: 41.31 (+0.53), LAD: 102.54 (+0.04), ABT: 48.35 (+1.23), TMO: 130.69 (-3.75), TROW: 82.59 (-0.21), SONS: 7.89 (+0.05), ALV: 120.22 (-3.47), GNTX: 18.26 (+0.09), BA: 151.19 (-2.14), TUP: 67.25 (-2.60), KNX: 32.62 (+0.07), STJ: 73.55 (+4.43), MCD: 97.84 (+2.97), AN: 65.83 (+0.93)

Potlatch Schedules First Quarter 2015 Earnings Release and Conference Call for April 22nd
GlobeNewswire - Tue Mar 24, 7:30AM CDT
Potlatch Corporation (Nasdaq CH) will release first quarter 2015 earnings results on Wednesday, April 22, 2015, before the market opens. A live conference call and webcast will follow hosted by Michael J. Covey, chairman and chief executive officer, at 9 a.m. Pacific Time (noon Eastern Time).
PCH: 37.47 (-0.65)

Comparing America's Next 3 Lumber Production Companies
Joseph Cafariello - at Seeking Alpha - Mon Mar 23, 2:48AM CDT

BCC: 38.42 (-0.13), PCH: 37.47 (-0.65), DEL: 64.32 (-0.02)

Upgrade Alert for Potlatch (PCH)
Comtex SmarTrend(R) - Fri Mar 13, 8:07AM CDT
Potlatch (NYSE CH) was upgraded from Neutral to Buy at DA Davidson today. The stock closed yesterday at $38.52 on volume of 317,000 shares, above average daily volume of 281,000. In the past 52 weeks, Potlatch share prices have been bracketed by a low of $37.04 and a high of $44.20 and closed yesterday at $38.52, 4% above that low price. Over the last five market days, the 200-day moving average (MA) has remained constant while the 50-day MA has declined 0.8%.
PCH: 37.47 (-0.65)

Global Plywood Industry Report 2015
M2 - Mon Feb 16, 10:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/lkwh7h/global_plywood) has announced the addition of the "Global Plywood Industry Report 2015" report to their offering. The Global Plywood Industry Report 2015 is a professional and in-depth study on the current state of the plywood industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The plywood market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are also discussed and manufacturing processes and cost structures analyzed. Plywood industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided. The report focuses on twenty-nine industry players providing information such as company profiles, product picture and specification, capacity production, price, cost, production value and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. The plywood industry development trends and marketing channels are analyzed. Finally the feasibility of new investment projects are assessed and overall research conclusions offered. Key Topics Covered: - Plywood Industry Overview - Plywood International and China Market Analysis - Plywood Technical Data and Manufacturing Plants Analysis - Plywood Production by Regions By Technology By Applications - Plywood Manufacturing Process and Cost Structure - Plywood Productions Supply Sales Demand Market Status and Forecast 2009-2014 - Plywood Key Manufacturers Analysis - Up and Down Stream Industry Analysis - Plywood Marketing Channels Analysis - Plywood Productions Supply Sales Demand Market Status and Forecast 2015-2020 - Plywood Supply Chain Relationship Analysis - Plywood New Project Investment Feasibility Analysis - Global Plywood Industry Research Conclusions Companies Mentioned - Boise Cascade - Columbia Forest Products - DeHua TB New Decoration Material - Fenglin - Fuxiang - Ganli - Georgia-Pacific - Greenply - Guangzhou Weizheng - Happy Group - Huangmao - Huaxin Jiasheng - Jinqiu - King Coconut Group - Luli Group - Penghong - Plum Creek Timber Company - Potlatch Corporation - RH GROUP - Roseburg - SAMLING - Samko Timber - Shengyang Industry - Swanson Group - Tengfei - UMP - West Fraser - Xingang - Zhejiang Shenghua Yunfeng Greeneo For more information visit http://www.researchandmarkets.com/research/lk...al_plywood
BCC: 38.42 (-0.13), PCH: 37.47 (-0.65), PCL: 42.31 (-0.18)

Potlatch Board Declares Distribution on Common Stock
GlobeNewswire - Fri Feb 13, 12:00PM CST
The board of directors of Potlatch Corporation (Nasdaq CH) has declared a quarterly distribution on the Company's common stock. The distribution of $0.375 per share is payable March 31, 2015 to stockholders of record on March 6, 2015.
PCH: 37.47 (-0.65)


Minnesota puts brakes on conversion of forests to crops
By STEVE KARNOWSKI - AP - Thu Feb 05, 4:45PM CST
MINNEAPOLIS (AP) — Minnesota officials on Thursday put the brakes on the rapid conversion of pine forests to potato fields in the northwestern part of the state while they conduct an environmental review to get a better understanding of the potential threats to groundwater, fish and wildlife.
PCH: 37.47 (-0.65)

How it All Plays Out: Special Research on Potlatch, Rediff, Premier Exhibitions, Premier, and PRGX Global
PR Newswire - Wed Feb 04, 8:00AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Potlatch (NASDAQ: PCH), Rediff (NASDAQ: REDF), Premier Exhibitions (NASDAQ: PRXI), Premier (NASDAQ: PINC), and PRGX Global (NASDAQ: PRGX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
PCH: 37.47 (-0.65), PRXI: 4.82 (+0.27), PRGX: 3.99 (+0.08), REDF: 1.98 (-0.04), PINC: 37.76 (unch)

Potlatch's (PCH) CEO Michael Covey on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Jan 28, 3:27PM CST

PCH: 37.47 (-0.65)

Can Weyerhaeuser Beat Q4 Earnings on Housing Recovery? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 1:00PM CST
Weyerhaeuser Company (WY) is scheduled to report fourth-quarter 2014 results on Jan 30, 2015 before the market opens. The Zacks Consensus Estimate for the quarter is pegged at 28 cents per share.
PCH: 37.47 (-0.65), WY: 31.75 (+0.14), SERV: 34.24 (+0.13), URI: 95.79 (-2.11)

Plum Creek Timber Getting A Little More Respect
Stephen Simpson, CFA - at Seeking Alpha - Wed Jan 28, 10:04AM CST

PCH: 37.47 (-0.65), PCL: 42.31 (-0.18), WY: 31.75 (+0.14)

Potlatch tops 4Q profit forecasts
Automated Insights - Wed Jan 28, 5:58AM CST
SPOKANE, Wash. (AP) _ Potlatch Corp. (PCH) on Wednesday reported fourth-quarter earnings of $20.1 million.
PCH: 37.47 (-0.65)

Potlatch beats by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Jan 28, 5:31AM CST

PCH: 37.47 (-0.65)

Potlatch Corporation Reports Fourth Quarter and Full Year 2014 Results
GlobeNewswire - Wed Jan 28, 5:30AM CST
Potlatch Corporation (Nasdaq CH) today reported net income of $20.1 million, or $0.49 per diluted share, on revenues of $146.2 million for the quarter ended December 31, 2014. Excluding transaction-related expenses of $0.4 million and nonrecurring tax benefits of $1.9 million, fourth quarter 2014 earnings were $18.6 million, or $0.45 per diluted share. Net income was $13.7 million, or $0.34 per diluted share, on revenues of $140.0 million in the fourth quarter of 2013.
PCH: 37.47 (-0.65)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

Updated Category News Views 54

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Continue Reading
Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Updated Category News Views 70

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Continue Reading
Sempra Shines with Robust Q3 2026 Financials

Updated Category News Views 0

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Continue Reading
Coastal Financial Faces Class Action Suit Over Securities

Updated Category News Views 78

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Continue Reading
Grant Davis Joins Assembly Health as CXO

Updated Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

Continue Reading
MAURE's Three-Year Mark: Crafting Home Elegance

Updated Category News Views 53

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Continue Reading
Dizal Unveils Promising Data at ASH 2026

Updated Category News Views 72

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

Continue Reading
LOA Roofing's Growth Recap Taps Southstone's Backing

Updated Category News Views 107

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

Continue Reading
SKF's Industrial Push: Energy Efficiency at COP31

Updated Category News Views 17

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Continue Reading
Eli Lilly's Retatrutide Trials Signal Innovation

Updated Category News Views 48

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...

Continue Reading

Top 5 Most Recently Viewed Articles

SKYX Technologies Expands Market Presence with Insider Investments

Updated Category News Views 166

SKYX Technologies' Corporate Developments SKYX Technologies, also known as SKYX (NASDAQ: SKYX), is taking significant strides in the smart technology sector. This dynamic company focuses on transforming homes and buildings into smarter, safer, and more advanced spaces. With a remarkable portfolio of over 97 issued and pending patents, SKYX aims to set a new standard in...

Continue Reading
Crinetics Pharmaceuticals Expands Workforce With Stock Options

Updated Category News Views 195

Crinetics Pharmaceuticals Enhances Employee Incentives In a recent announcement, Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX), based in San Diego, revealed a significant step in enhancing employee incentives and strengthening its workforce. On October 10, 2025, the company’s Compensation Committee authorized the granting of stock options and restricted stock units...

Continue Reading
Manulife Investment Management Earns Top Recognition in Sustainable Finance

Updated Category News Views 199

Manulife Investment Management Recognized for Excellence In a significant acknowledgment of its leadership in sustainable finance, Manulife Investment Management (Manulife IM) has made it to the prestigious list of IPE Real Assets' Top 50 Natural Capital Managers. This recognition comes as the firm is gearing up for robust fundraising activities, with an exciting fund...

Continue Reading
Vaxart Reports Progress and Financial Performance for Q3 2025

Updated Category News Views 213

Vaxart’s Business Progress and Financial Results Overview Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company, recently provided a significant update on its business and reported its financial outcomes for the third quarter of 2025. This latest communication showcases exciting developments in their oral recombinant vaccine platform, which is designed to...

Continue Reading
Madrigal Pharmaceuticals Marks Enrollment Milestone in NASH Study

Updated Category News Views 47

Madrigal Pharmaceuticals Achieves Enrollment Milestone in NASH Study Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company dedicated to developing innovative therapies for liver diseases, has announced a significant milestone in their MAESTRO-NASH OUTCOMES clinical trial. This study evaluates the efficacy of resmetirom in patients diagnosed with...

Continue Reading